TCGA-55-6979-01A-11R-1949-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.630
- INTERFERON_ALPHA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.520
- INFLAMMATORY_RESPONSE+0.520
- COMPLEMENT+0.470
- KRAS_SIGNALING_UP+0.450
- ANGIOGENESIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- IL2_STAT5_SIGNALING+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.480
- OXIDATIVE_PHOSPHORYLATION-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.340
- DNA_REPAIR-0.300
- PROTEIN_SECRETION-0.280
- WNT_BETA_CATENIN_SIGNALING-0.270
- FATTY_ACID_METABOLISM-0.250
- ADIPOGENESIS-0.240
- E2F_TARGETS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.927 |
| 2 | DRR168577 | — | — | 0.920 |
| 3 | BS_JBGZ7HHZ | ganglioneuroblastoma | — | 0.909 |
| 4 | 897de94a-21ad-4ec5-b50b-1a84370f41a0 | — | — | 0.908 |
| 5 | C3L-03976 | — | cohortMD2 | 0.905 |
| 6 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.900 |
| 7 | SRR8613789 | — | A | 0.898 |
| 8 | SRR821602 | GTEX | — | 0.896 |
| 9 | TCGA-21-1076-01A-01R-0692-07 | — | cohortSQ1 | 0.895 |
| 10 | 767fc312-2c66-43f7-b78e-bf79e03e3a0a | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |